MiguelAngelMaterinMD

Ocular Oncology

Physician

Dr. Materin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Miguel Materin is an ophthalmologist in Durham, NC and is affiliated with Duke University Hospital.

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

7 citations
Improved Prognostic Precision in Uveal Melanoma through a Combined Score of Clinical Stage and Molecular Prognostication.
Andrew W Stacey, Vaidehi S Dedania, Miguel Materin, Hakan Demirci
Ocular Oncology and Pathology. 2022-02-01
18 citations
Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma.
Hakan Demirci, Leslie M. Niziol, Zeynep Gursel Ozkurt, Naziha Slimani, Cem Ozgonul
American Journal of Ophthalmology. 2018-08-04
893 citations
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Michael Krauthammer, Yong Lin Kong, Byung Hak Ha, Perry Evans, Antonella Bacchiocchi
Nature Genetics. 2012-09-01

Metastatic Uveal Melanoma: New Drugs in Pipeline, but Prognoses Remain GrimDecember 14th, 2021
Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5May 1st, 2020